Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Inavolisib (Itovebi)

decorative image of the issue cover

Published April 1, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses inavolisib (Itovebi), 3 mg and 9 mg, film-coated oral tablet.
  • Indication: Inavolisib in combination with palbociclib and fulvestrant is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA‑mutated, hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.